Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OMER vs ENTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Captures Overall Composite Edge (54.1 HOLD vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars

OMER Overall Winner 6-Pillar Tally: OMER 2 – 3 ENTA (1 Tie) Matrix Metrics: OMER 7 – 3 ENTA

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (54.1/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, Options & Positioning), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. OMER trades at $16.68 (75.8x Forward P/E, -189.5% operating margin) versus ENTA at $10.67 (44.0x Forward P/E, -90.0% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.82β · 54% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OMER vs ENTA
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$16.68
-4.63% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 75.8x
Beta / 30D Vol 1.82β · 54% Vol
Unified Composite Score
54.1 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 74.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $17.47 · SMA50: $18.23
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.67
-2.91% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.88β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88

6-Pillar Scorecard Institutional Category Breakdown (OMER 2 – 3 ENTA)

Columns: Metric · OMER · ENTA
1. Valuation Multiples ENTA
Forward P/E 75.8x 44.0x
Trailing P/E 14.9x 44.0x
PEG Ratio 0.81x N/M
EV / Revenue 51.9x 5.3x
2. Growth & Scale OMER
Revenue Growth (YoY) +14.9% -21.6%
Earnings Growth (YoY) +0.0% -66.2%
TTM Revenue (USD) $27M $65M
Market Cap $1.3B $326.2M
3. Profitability & Quality ENTA
Gross Margin 38.3% 100.0%
Operating Margin -189.5% -90.0%
Net Profit Margin 324.9% -96.9%
Return on Equity (ROE) -576.3% -70.1%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$48M -$37M
Cash Flow Margin N/A -56.6%
Net Cash / Leverage $96M Net Debt $22M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OMER
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 147.9% (99th %ile) 78.7% (11th %ile)
Put/Call OI Skew 0.09x (Call-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OMER (7) vs ENTA (3)
Institutional Metric OMER ENTA Criterion Row Edge
Market Capitalization
Scale
$1.3B $326.2M Larger Scale OMER
Trailing P/E Ratio
Valuation
14.9x 44.0x Lower Multiple OMER
Forward P/E Ratio
Valuation
75.8x 44.0x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
+14.9% -21.6% Higher Growth OMER
Operating Margin (TTM)
Profitability
-189.5% -90.0% Higher Margin ENTA
Net Profit Margin
Profitability
324.9% -96.9% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-576.3% -70.1% Higher ROE ENTA
52-Week Range Position
Momentum
70% ($6–$21) 9% ($10–$17) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
1.82β · 54% Vol 0.88β · 58% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
54.1 / 100 (HOLD) 46.2 / 100 (HOLD) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
$27M $65M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
38.3% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 51.9x EV/Rev N/M PEG · 5.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($96M Net Debt) -$37M ($22M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OMER +6.83 pp
OMER: +2.96% · ENTA: -3.87%
3M Horizon OMER +16.8 pp
OMER: -2.97% · ENTA: -19.77%
6M Horizon OMER +63.23 pp
OMER: +42.56% · ENTA: -20.67%
1Y Horizon OMER +174.57 pp
OMER: +165.61% · ENTA: -8.96%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OMER Revenue ENTA Revenue OMER Op. Margin ENTA Op. Margin Margin Leader
FY2018 $30M $210M -375.7% 42.7% ENTA
FY2019 $110M $210M -130.6% 17.9% ENTA
FY2020 $70M $120M -212.6% -34.0% ENTA
FY2021 N/A $100M N/A -112.9% ENTA
FY2022 N/A $90M N/A -143.7% ENTA
FY2023 N/A $80M N/A -173.2% ENTA
FY2024 N/A $70M N/A -179.9% ENTA
FY2025 N/A $70M N/A -130.7% ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OMER CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 147.9%
IV Percentile 99th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OMER vs ENTA Key Questions & Quantitative Answers

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (54.1/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, Options & Positioning), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. OMER trades at $16.68 (75.8x Forward P/E, -189.5% operating margin) versus ENTA at $10.67 (44.0x Forward P/E, -90.0% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.82β · 54% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OMER leads the Growth & Scale pillar: OMER posts +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OMER cumulative revenue shifted +133.3% while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, OMER deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.

ENTA screens cheaper on headline valuation multiples. OMER trades at 75.8x Forward P/E, 14.9x Trailing P/E, 0.81x PEG, and 51.9x EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OMER (-576.3% ROE) versus ENTA (-70.1% ROE) capital efficiency.

In options market volatility and institutional positioning, OMER carries 147.9% implied volatility (99th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.82β · 54% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.88β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.